Memo Therapeutics AG is a late-stage biotech company developing therapeutic antibodies for virus infections and cancer. Their lead program, AntiBKV, is a neutralizing antibody for treating BK virus infection in kidney transplant recipients. They also have a pipeline of antibodies targeting infectious diseases and immuno-oncology. Their technology platform enables high-throughput screening and identification of potent antibodies.

Memo Therapeutics AG

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.

Its DROPZYLLA™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. Combined with our microfluidic high throughput single cell-based functional screening system this leads to entirely new possibilities in immune repertoire analysis and antibody discovery.

The business strategy of Memo Therapeutics is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. DROPZYLLA™ is deployed in proprietary antibody discovery programs and is made available in collaborations e.g. for screening of CAR-T; TCR-T or bi-specific antibodies.

Federal Office of Public Health (FOPH) Switzerland

Schroder Adveq

Zürcher Kantonal Bank

Verve Ventures

Redalpine

Bernina BioInvest

Jaquet Partners

Swisscanto Private Equity

Adjuvant Capital

Fresenius Medical Care

Vesalius Biocapital Partners

GF Group Holding

“AntiBKV has the potential to be a best- and first-in-class antibody for the treatment of BKV infection in kidney transplant recipients. With 50,000 kidney transplant procedures carried out in the US and Europe alone, AntiBKV addresses a large and rapidly growing market, with an estimated size well beyond USD 1 billion,” said Karsten Fischer, Chief Executive Officer of Memo Therapeutics AG.

#clinicaltrials #phase1 

https://lnkd.in/erjNXiGc

Metric
Company Name	Memo Therapeutics AG
Symbol
MSH ID	COM:MEMO-THERAPEUTICS
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology
Country	CH
Stage	Series C
Employee Count	11
Website	memo-therapeutics.com
LinkedIn	memo-therapeutics-ag
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.63K
Web Traffic Growth	-0.32
Valuation
Raised Capital	22.02M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	13.84
28-Day Growth Score	17.60
90-Day Growth Score	15.12
365-Day Growth Score	73.56

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:MEMO-THERAPEUTICS

Memo Therapeutics AG

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue